



## Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- [Dyne Therapeutics, Inc.](https://www.dyne-tx.com) (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne's website at <https://investors.dyne-tx.com/news-and-events/events-and-presentations> and a replay will be accessible for 30 days following the presentation.

### About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of therapeutic candidates for serious muscle diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit <https://www.dyne-tx.com/>, and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### Contact:

Dyne Therapeutics  
Amy Reilly  
[areilly@dyne-tx.com](mailto:areilly@dyne-tx.com)  
857-341-1203